Janux announces encouraging safety/efficacy data for JANX007 in mCRPC and JANX008 in solid tumors

Janux Therapeutics, Inc.

JANX007: 5/6 (83%) PSA50 declines at step dose ≥0.2 mg; 10/18 (56%) at ≥0.1 mg; no Grade 3+ CRS.
JANX008: NSCLC subject achieved confirmed PR with 100% target lung lesion reduction and elimination of liver metastasis; no CRS or TRAEs.
JANX008: No Grade 2+ CRS, no treatment-related SAEs or DLTs across 11 heavily pretreated patients across 4 tumor types.
Janux hosting virtual investor event today at 4:30 PM ET to discuss data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.